JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Authors
Keywords
-
Journal
POSTGRADUATE MEDICINE
Volume -, Issue -, Pages 1-19
Publisher
Informa UK Limited
Online
2020-11-27
DOI
10.1080/00325481.2020.1855921
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer
- (2020) Sufang Tian et al. Journal of Thoracic Oncology
- Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
- (2020) Ning Wang et al. Frontiers in Microbiology
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
- (2020) Nature Microbiology
- Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2
- (2020) Sairaj Satarker et al. ARCHIVES OF MEDICAL RESEARCH
- Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2
- (2020) Ren-Di Jiang et al. CELL
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
- (2020) Carly G.K. Ziegler et al. CELL
- JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
- (2020) Farhad Seif et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports
- (2020) Valeria Gaspari et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Association of inflammatory markers with the severity of COVID-19: a meta-analysis
- (2020) Furong Zeng et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach
- (2020) Salman Ali Khan et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Patients with Coronavirus Disease 2019: A Retrospective Cross‐sectional Study
- (2020) Xisheng Yan et al. JOURNAL OF MEDICAL VIROLOGY
- TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
- (2020) Dandan Wu et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
- (2020) Linlin Bao et al. NATURE
- Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
- (2020) Barry Rockx et al. SCIENCE
- Focal status epilepticus as unique clinical feature of COVID-19: A case report
- (2020) Catello Vollono et al. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
- The Viral Macrodomain Counters Host Antiviral ADP-Ribosylation
- (2020) Yousef M. O. Alhammad et al. Viruses-Basel
- Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
- (2020) Wen Wen et al. Cell Discovery
- JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients
- (2020) Patricio Rojas et al. ACTA HAEMATOLOGICA
- Expansion of Single Cell Transcriptomics Data of SARS-CoV Infection in Human Bronchial Epithelial Cells to COVID-19
- (2020) Reza Zolfaghari Emameh et al. BIOLOGICAL PROCEDURES ONLINE
- Expression of ACE2 in Human Neurons Supports the Neuro-Invasive Potential of COVID-19 Virus
- (2020) Jiaxi Xu et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Rationale for targeting complement in COVID‐19
- (2020) Anastasia Polycarpou et al. EMBO Molecular Medicine
- JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk
- (2020) Puja Mehta et al. EUROPEAN RESPIRATORY JOURNAL
- Pulmonary immune responses against SARS-CoV-2 infection: harmful or not?
- (2020) A. Guillon et al. INTENSIVE CARE MEDICINE
- A dissection of SARS‑CoV2 with clinical implications (Review)
- (2020) Felician Stancioiu et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Attenuated Interferon and Proinflammatory Response in SARS-CoV-2–Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation
- (2020) Dong Yang et al. JOURNAL OF INFECTIOUS DISEASES
- Cytokine storm syndrome in coronavirus disease 2019: A narrative review
- (2020) Y.‐M. Gao et al. JOURNAL OF INTERNAL MEDICINE
- Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts
- (2020) Jin Wang et al. JOURNAL OF LEUKOCYTE BIOLOGY
- COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection?
- (2020) Ritwick Mondal et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
- (2020) F. La Rosée et al. LEUKEMIA
- Clinical presentation and management of COVID ‐19
- (2020) Irani Thevarajan et al. MEDICAL JOURNAL OF AUSTRALIA
- Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
- (2020) Donghyuk Shin et al. NATURE
- Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19
- (2020) Sarah C.J. Jorgensen et al. PHARMACOTHERAPY
- Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
- (2020) Divij Mathew et al. SCIENCE
- SARS-CoV-2 infection and stem cells: Interaction and intervention
- (2020) Fenggang Yu et al. Stem Cell Research
- Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
- (2020) Wei Luo et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A Putative Role of de-Mono-ADP-Ribosylation of STAT1 by the SARS-CoV-2 Nsp3 Protein in the Cytokine Storm Syndrome of COVID-19
- (2020) Jean-Michel Claverie Viruses-Basel
- Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies
- (2020) Marisa Market et al. Frontiers in Immunology
- Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper
- (2020) Sonu Bhaskar et al. Frontiers in Immunology
- The COVID-19 Cytokine Storm; What We Know So Far
- (2020) Dina Ragab et al. Frontiers in Immunology
- The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)
- (2020) Pere Domingo et al. EBioMedicine
- Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis
- (2020) Xudong Feng et al. Frontiers in Medicine
- Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol
- (2020) Enrico Capochiani et al. Frontiers in Medicine
- Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19
- (2020) Joseph Meletiadis et al. Infectious Diseases and Therapy
- Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
- (2020) Theresa Klemm et al. EMBO JOURNAL
- Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19
- (2020) Xiuhong Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Tackling the cytokine storm in COVID-19, challenges and hopes
- (2020) Shifaa M. Abdin et al. LIFE SCIENCES
- Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions
- (2020) Abdollah Jafarzadeh et al. LIFE SCIENCES
- The importance of cell-mediated immunity in COVID-19 – An opinion
- (2020) Henna Iqbal MEDICAL HYPOTHESES
- COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City
- (2020) Alain C. Borczuk et al. MODERN PATHOLOGY
- Evasion of Type I Interferon by SARS-CoV-2
- (2020) Hongjie Xia et al. Cell Reports
- Measurement of Cellular Immune Response to Viral Infection and Vaccination
- (2020) Wilbert Bouwman et al. Frontiers in Immunology
- Cytokine Storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in”
- (2020) Vanessa Castelli et al. Frontiers in Immunology
- SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2
- (2020) Jingfang Mu et al. Cell Discovery
- Involvement of the nervous system in COVID-19: The bell should toll in the brain
- (2020) Sairaj Satarker et al. LIFE SCIENCES
- IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis
- (2019) Marina von Essen et al. Cells
- T-Cell Protein Tyrosine Phosphatase Is Irreversibly Inhibited by Etoposide-Quinone, a Reactive Metabolite of the Chemotherapy Drug Etoposide
- (2019) Qing Nian et al. MOLECULAR PHARMACOLOGY
- Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
- (2019) Alessia Alunno et al. Cells
- Transcriptional, Epigenetic and Pharmacological Control of JAK/STAT Pathway in NK Cells
- (2019) Gianluca Scarno et al. Frontiers in Immunology
- JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation
- (2019) Dagmar Gotthardt et al. Frontiers in Immunology
- Targeting STAT3 in Cancer with Nucleotide Therapeutics
- (2019) Yue-Ting K. Lau et al. Cancers
- JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
- (2019) Katie L. Owen et al. Cancers
- The regulation of JAKs in cytokine signaling and its breakdown in disease
- (2018) Henrik M. Hammarén et al. CYTOKINE
- The molecular basis of JAK/STAT inhibition by SOCS1
- (2018) Nicholas P. D. Liau et al. Nature Communications
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
- (2018) Emira Bousoik et al. Frontiers in Oncology
- Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation
- (2018) Guo-Juan Niu et al. Frontiers in Immunology
- Inflammatory responses and inflammation-associated diseases in organs
- (2017) Linlin Chen et al. Oncotarget
- SOCS Proteins as Regulators of Inflammatory Responses Induced by Bacterial Infections: A Review
- (2017) Skyla A. Duncan et al. Frontiers in Microbiology
- The Complex Role of STAT3 in Viral Infections
- (2015) Suresh V. Kuchipudi Journal of Immunology Research
- Protein Tyrosine Phosphatase 1B Is a Regulator of the Interleukin-10-Induced Transcriptional Program in Macrophages
- (2014) K. A. Pike et al. Science Signaling
- Therapeutic modulators of STAT signalling for human diseases
- (2013) Gabriella Miklossy et al. NATURE REVIEWS DRUG DISCOVERY
- Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis
- (2013) Srdan Verstovsek POSTGRADUATE MEDICINE
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
- (2012) John J. O'Shea et al. IMMUNITY
- Cytokine release from innate immune cells: association with diverse membrane trafficking pathways
- (2011) P. Lacy et al. BLOOD
- Natural Killer Cell Education and Tolerance
- (2010) Mark T. Orr et al. CELL
- Induction and effector functions of TH17 cells
- (2008) Estelle Bettelli et al. NATURE
- SOCS regulation of the JAK/STAT signalling pathway
- (2008) Ben A. Croker et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started